Document is current
Any future updates will be listed below
-
Authors
Rossi, Tania
Bandini, Sara
Zanoni, Michele
Cortesi, Michela
Palleschi, Michela
Bandini, Erika
Rocca, Andrea
Gallerani, Giulia
Vannini, Ivan
Plousiou, Meropi
Gerratana, Lorenzo
Musolino, Antonino
Tallini, Giovanni
Martinelli, Giovanni
De Giorgi, Ugo
Ulivi, Paola
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 18 April 2025
First Online: 6 May 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Romagna Ethics Committee (CEROM) of Meldola: Protocol code IRST174.19 (November 9 2018) and IRSTB114 (June 6 2020). All the patients gave and signed their informed consent to participate the study and for publication.
: All the patients gave and signed their informed consent to participate the study and for publication.
: Dr Palleschi reports honoraria for educational events/materials from Novartis, Daiichi-Sankyo, Gilead and travel, accommodations, and/or expenses from Grant from Novartis, Astrazeneca and Lilly. Prof Musolino reports research funding from Lilly and Roche and consulting or advisory role for Lilly, Eisai Europe, Seagen, Daiichi Sankyo/Astra Zeneca and Novartis. No other disclosures were reported.
